Table 4 Adverse effects of liposomal irinotecan.
From: Cancer nanomedicine: a review of recent success in drug delivery
|  | Most common grade 3–4 adverse events | |||||
|---|---|---|---|---|---|---|
PEPO2 | Irinotecan | Docetaxel | ||||
N | % | n | % | n | % | |
Anaemia | 2 | 4.5 | 2 | 4.5 | 3 | 6.8 |
Neutropaenia | 5 | 11.4 | 7 | 15.9 | 2 | 2.6 |
Thrombocytopenia | 1 | 2.3 | 1 | 2.3 | 0 | 0 |
Febrile neutropenia | 3 | 6.8 | 5 | 11.3 | 2 | 2.6 |
Diarrhoea | 12 | 27.3 | 8 | 18.2 | 1 | 2.3 |
Nausea | 5 | 11.4 | 2 | 4.6 | 0 | 0 |
Vomiting | 2 | 4.6 | 6 | 13.6 | 3 | 6.8 |
Anorexia | 3 | 6.8 | 3 | 6.8 | 0 | 0 |
Fatigue | 2 | 4.6 | 1 | 2.3 | 1 | 2.3 |